Leerink Partnrs Analysts Cut Earnings Estimates for Danaher

Danaher Co. (NYSE:DHR) – Equities research analysts at Leerink Partnrs decreased their Q2 2025 earnings per share estimates for shares of Danaher in a note issued to investors on Wednesday, January 29th. Leerink Partnrs analyst P. Souda now expects that the conglomerate will post earnings of $1.74 per share for the quarter, down from their previous estimate of $1.88. The consensus estimate for Danaher’s current full-year earnings is $8.15 per share. Leerink Partnrs also issued estimates for Danaher’s Q3 2025 earnings at $1.85 EPS.

Several other brokerages also recently weighed in on DHR. Wolfe Research raised Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price target on the stock in a research report on Thursday, October 31st. KeyCorp boosted their target price on shares of Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 23rd. TD Cowen lifted their target price on shares of Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a research note on Wednesday, October 23rd. Jefferies Financial Group cut their target price on Danaher from $285.00 to $260.00 and set a “buy” rating for the company in a research note on Wednesday. Finally, Stephens reissued an “overweight” rating and set a $315.00 price target on shares of Danaher in a research report on Wednesday, October 23rd. Six investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $278.00.

Danaher Stock Performance

Shares of DHR opened at $223.16 on Friday. The stock has a 50-day moving average of $235.89 and a two-hundred day moving average of $253.45. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. The stock has a market cap of $161.19 billion, a P/E ratio of 42.27, a P/E/G ratio of 4.22 and a beta of 0.83. Danaher has a one year low of $221.34 and a one year high of $281.70.

Danaher (NYSE:DHR) last released its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, meeting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.72% and a net margin of 16.33%. During the same period in the previous year, the firm earned $2.09 earnings per share.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be issued a dividend of $0.27 per share. The ex-dividend date is Friday, December 27th. This represents a $1.08 annualized dividend and a yield of 0.48%. Danaher’s payout ratio is 20.45%.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Heck Capital Advisors LLC acquired a new position in Danaher in the fourth quarter worth approximately $27,000. Decker Retirement Planning Inc. acquired a new position in shares of Danaher in the 4th quarter worth $31,000. Golden State Wealth Management LLC acquired a new stake in shares of Danaher during the fourth quarter worth $31,000. Teachers Insurance & Annuity Association of America acquired a new position in shares of Danaher in the 3rd quarter valued at $39,000. Finally, MidAtlantic Capital Management Inc. purchased a new position in shares of Danaher in the third quarter worth approximately $40,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.